Angiotensin Converting Enzyme Inhibitors May Cause Renal Impairment in Diabetes Mellitus

1988 ◽  
Vol 33 (2) ◽  
pp. 247-248 ◽  
Author(s):  
J. Webster ◽  
L.E. Murchison ◽  
O.J. Robb
Keyword(s):  
Diabetes Mellitus ◽  
Renal Function ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Diabetic Patients ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Careful Investigation

Angiotensin converting enzyme (ACE) inhibitors have been recommended for the treatment of diabetic nephropathy. However, it should be remembered that diabetic patients may also develop atheromatous renal artery stenosis. In such patients ACE inhibitors may have adverse effects on renal function. Careful investigation and monitoring is essential when ACE inhibitors are used in diabetes.

scholarly journals Medicines in the rehabilitation of patients after myocardial infarction: angiotensin-converting enzyme inhibitors

2010 ◽  
Vol 1 (1) ◽  
pp. 62-64
Author(s):  
A. S Galyavich
Keyword(s):  
Myocardial Infarction ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitors ◽  
Ventricular Dysfunction ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Left Ventricular ◽  
Diabetic Patients ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

The paper analyzes the use of angiotensin-converting enzyme (ACE) inhibitors in patients after prior myocardial infarction. It presents the data of controlled studies, which indicate that it is warranted to use ACE inhibitors to improve prognosis in patients. It is concluded that it is unreasonable for a physician not to prescribe ACE inhibitors to post-myocardial infarction patients with obvious or asymptomatic left ventricular dysfunction and to diabetic patients (if no contraindications).

scholarly journals Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients

2017 ◽  
Vol 46 (2) ◽  
pp. 150-155 ◽  
Author(s):  
Silvia Carreira Ribeiro ◽  
Ana Elizabeth Figueiredo ◽  
Pasqual Barretti ◽  
Roberto Pecoits-Filho ◽  
Thyago Proença de Moraes ◽  
...  
Keyword(s):  
Renal Function ◽  
Peritoneal Dialysis ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Serum Levels ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Dialysis Patients ◽  
Converting Enzyme Inhibitors ◽  
Renin Angiotensin

Background: The chronic use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker has been associated with hyperkalemia in patients with reduced renal function even after the initiation of hemodialysis. Whether such medications may cause a similar effect in peritoneal dialysis patients is not well established. So, the aim of our study was to analyze the impact of renin-angiotensin-aldosterone inhibitors on the serum levels of potassium in a national cohort of peritoneal dialysis patients. Method: A prospective, observational, nationwide cohort study was conducted. We identified all incident patients on peritoneal dialysis that had angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) prescribed for at least 3 months and a similar period of time without these medications. Patients were divided into 4 groups: Groups I and III correspond to patients using, respectively, an ACEi or ARB and then got the drug suspended; Groups II and IV started peritoneal dialysis without the use of any renin-angiotensin aldosterone system inhibitor and then got, respectively, an ACEi or ARB introduced. Changes in potassium serum levels were compared using 2 statistical approaches: (1) the non-parametric Wilcoxon test for repeated measures and (2) a crossover analysis. Results: Mean potassium serum levels at the first phase of the study for Groups I, II, III, and IV were, respectively, 4.46 ± 0.79, 4.33 ± 0.78, 4.41 ± 0.63, and 4.44 ± 0.56. Changes in mean potassium serum levels for Groups I, II, III, and IV were -0.10 ± 0.60, 0.02 ± 0.56, -0.06 ± 0.46, and 0.03 ± 0.50, respectively. Conclusion: The use of ACEi and ARB was not associated with a greater risk for hyperkalemia in stable peritoneal dialysis patients independently of residual renal function.

Sign in / Sign up

Export Citation Format

Share Document